Imaging in motor neuron diseases; biomarker research with MRI - Imaging in MND

niversitair Medisch Centrum Utrecht0 个研究点目标入组 2,203 人开始时间: 待定最近更新: 2024年5月6日

试验速览

暂无简介。

•1a) Patients: i) For ALS patients: definite, probable, probable-laboratory
•supported or possible ALS according to the revised El Escorial criteria (Brooks
•2000); familial ALS is defined only if there is a family history of ALS. ii)
•For progressive spinal muscular atrophy (PSMA) or primary lateral sclerosis
•(PLS): patients with clinical diagnosis of PSMA or PLS, after excluding other
•diseases. iii) Patients with *ALS mimic syndromes*: patients suspected of /with
•mimic disorders (e.g. multifocal motor neuropathy, inclusion body myositis,
•cervical myeloradiculopathy, myasthenia gravis, Kennedy*s disease, spinal
•muscular atrophy).
•1b) Healthy controls without manifest diagnosis of motor neuron disease or ALS
•2. Age 18 - 80 years (inclusive).
•3. Capable of thoroughly understanding the study information given; has signed
•the informed consent.

•1) Tracheostomy, tracheostomal ventilation of any type, (non)-invasive
•ventilation; 2 ) Any history or presence of brain injury, epilepsy, psychiatric
•illness and other cerebral disease; 3) Any intoxication or medication known to
•have an association with motor neuron dysfunction, which might confound or
•obscure the diagnosis of motor neuron disease; 4) Presence of pronounced
•swallowing disorders (which make it dangerous to lie supine in the MRI
•scanner); 5) Contra-indication for 3Tesla MRI imaging (as established by the
•radiology department); 6) Pregnancy

发起方

niversitair Medisch Centrum Utrecht